Neurosoft Bioelectronics Names Sam Hosovsky Vice President of NeuroAI
Appointment marks Neurosoft's expansion beyond stretchable BCI hardware into neural data and AI models for decoding the human cortex, advancing its goal of turning brain interfaces into products people genuinely need.
Appointment marks Neurosoft's expansion beyond stretchable BCI hardware into neural data and AI models for decoding the human cortex, advancing its goal of turning brain interfaces into products people genuinely need.
GENEVA & NEW YORK — July 7, 2026 — Neurosoft Bioelectronics, a neurotechnology company developing scalable and safe brain-computer interfaces (BCIs), today announced the appointment of Sam Hosovsky as Vice President of NeuroAI. Hosovsky will lead the company's NeuroAI strategy and the neural foundation models set to power the next generation of high-performance brain interfaces, extending Neurosoft's mission from the stretchable electrodes it places on the cortex to the intelligence that makes the resulting data useful.
The appointment marks the next stage of Neurosoft's evolution, broadening from stretchable BCI hardware into the neural data and AI systems that turn recordings into real-world products, targeting a range of neural activity across the conditions its platform addresses, including motor restoration for people with paralysis. That work positions Neurosoft as a bridge between computational neuroscience and machine learning, running in both directions: bringing frontier AI to the problem of brain decoding, and the open problems of brain decoding back to frontier AI: an AI4Brain and Brain4AI exchange that few organizations are positioned to enable.
"Our soft electrode platform gives us neural data at a quality and scale no other approach can safely match, but data and hardware are only half the story," said Nicolas Vachicouras, PhD, CEO and Co-Founder of Neurosoft Bioelectronics. "Turning that data into products people genuinely need, such as restoring movement for people with paralysis, demands as much ambition in AI as in engineering. Sam has spent his whole career at that intersection, always starting from the end user. Bringing him on to lead NeuroAI is the natural next chapter for Neurosoft."
Hosovsky joins Neurosoft after nearly 5 years building software for intracranial BCI users through the uCat App, working alongside leading motor-BCI startups, research laboratories, clinicians, and patient organizations. His work has centered on translating intracranial signals into practical products for people with paralysis, giving him a rare perspective that spans the end-user experience, AI, and neural decoding, a perspective he set out in the first book dedicated to intracranial motor-BCI applications, "Your Cortical Avatar Technology."
"For nearly a decade I've been searching for a BCI that could reliably decode dexterous, whole-body movement and truly improve the lives of people with paralysis, at a scale that could eventually reach millions," said Hosovsky. "The field has spent years perfecting hardware; the opportunity now is to start with the user and work backwards to the technology. Neurosoft is the only interface that can chronically span all of the cortical areas involved in movement at once. Our challenge is to interpret that newfound orchestra as a coherent symphony."
Before joining Neurosoft, Hosovsky built a career architecting software platforms at the intersection of artificial intelligence, life sciences, and emerging technologies, spanning laboratory automation, clinical-trial infrastructure, generative AI, and extended reality, leading multidisciplinary engineering organizations and delivering production systems adopted by global pharmaceutical and research organizations. He is also a Partner at Jumpspace Ventures, one of the world's most active brain-
technology investment firms, where he leads technical due diligence across high-resolution BCIs, connectome-inspired AI, neural foundation models, and neural tissue engineering.
About Neurosoft Bioelectronics
Neurosoft Bioelectronics is a neurotechnology company developing stretchable and scalable brain-computer interfaces, with headquarters in Geneva, Switzerland and a US subsidiary in New York. Spun out of EPFL, the company's proprietary soft, stretchable electrode platform provides full-cortical access without penetrating brain tissue, enabling high-quality neural data acquisition. Neurosoft holds ISO 13485:2016 certification and has conducted first-in-human clinical studies at UTHealth Houston (US) and UMC Utrecht (Netherlands). Learn more at www.neurosoft-bio.com.
Media Contact
Nicolas Vachicouras, PhD — CEO & Co-Founder nicolas@neurosoft-bio.com
+41 78 876 14 69 (CH) | +1 914 233 4172 (US)
169 Madison Ave # 11497, New York, NY 10016 // Chemin des Mines 15bis, 1202 Geneva, Switzerland
Neurosoft Bioelectronics welcomes two leading advisors in neuro AI
Neurosoft Bioelectronics welcomes two leading advisors in neuro AI
Geneva, Switzerland, July 31 2025 - Neurosoft Bioelectronics SA, a Swiss company with a US presence in New York, developing scalable implantable brain-computer interfaces, is pleased to announce that Prof. Guillaume Lajoie and Prof. Martin Schrimpf have joined as scientific advisors to support the company’s strategy in neuro artificial intelligence and foundation brain modeling.
Geneva, Switzerland, July 31 2025 - Neurosoft Bioelectronics SA, a Swiss company with a US presence in New York, developing scalable implantable brain-computer interfaces, is pleased to announce that Prof. Guillaume Lajoie and Prof. Martin Schrimpf have joined as scientific advisors to support the company’s strategy in neuro artificial intelligence and foundation brain modeling.
This strategic addition reinforces Neurosoft’s ambition to build a foundation model of the brain trained on large-scale brain recordings, enabled by the company’s soft and high-resolution electrodes that can safely and stably cover a large cortical surface.
Prof. Guillaume Lajoie is Associate Professor at the University of Montréal and a core academic member of Mila, the Quebec AI Institute. His research explores mathematical tools and algorithms for brainmachine interfaces, and contributes to the responsible use of AI in scientific and clinical contexts. He was a leading author of POYO, one of the first neuro foundation models designed to decode large-scale neural activity from spike-level data.
Prof. Martin Schrimpf is a tenure-track Assistant Professor at EPFL and leads the NeuroAI research group at the EPFL Neuro-X Institute. His work combines deep learning, neuroscience, and cognitive science to build artificial neural networks that reproduce the brain’s internal representations and align with human behavior. After completing his PhD at MIT, he contributed to landmark studies in vision and language, and is the founder of the Brain-Score.org benchmarking platform.
“As we advance our clinical studies, we are exploring how our scalable and high-quality brain recordings could enable the development of foundation models,” said Dr. Nicolas Vachicouras, CEO and Co-Founder of Neurosoft Bioelectronics. “Guillaume and Martin bring exceptional expertise at the intersection of neuroscience and AI. Their guidance will be key as we work toward better brain decoding, biomarker discovery, and ultimately a general-purpose model of human brain function and cognition.”
Switzerland is emerging as a leader in AI foundation model research. Its national supercomputing center in Lugano inaugurated the Alps supercomputer in 2024, now ranked among the fastest systems in the world. The system has already been used to train open-source large language models developed by EPFL in collaboration with ETH Zurich, the Swiss National Supercomputing Centre (CSCS), and the Swiss Data Science Center (SDSC). As a spin-off from EPFL, Neurosoft Bioelectronics benefits from Switzerland’s strong academic and AI ecosystem. This positions the company to bridge high-quality clinical brain data with advanced AI models, enabling next-generation brain computer interfaces.
Swiss company sets record for most electrodes in a soft and stretchable brain interface tested in a human
Swiss company sets record for most electrodes in a soft and stretchable brain interface tested in a human
Geneva, Switzerland / Utrecht, Netherlands – 27-Feb-2025 – Neurosoft Bioelectronics SA, a Swiss neurotechnology startup based at Campus Biotech in Geneva, has achieved a major milestone with the successful testing of its high channel count brain interface in the first two human patients. This milestone was reached in February 2025 at University Medical Center (UMC) Utrecht, where a team led by Professor Maeike Zijlmans employed the device during epilepsy surgery.
This novel brain interface is designed to detect key epilepsy biomarkers - high-frequency oscillations and fast ripples - allowing surgeons to identify epileptic tissue with unprecedented precision during the procedure. With 64 sensing channels embedded in a stretchable material that is 1,000 to 100,000 times softer than conventional electrodes, the device conforms seamlessly to the brain's surface. This softness improves comformability with the brain, while ensuring high-resolution neural recordings, helping neurosurgeons distinguish between healthy and epileptic tissue more accurately, thereby reducing the risk of either excessive or insufficient tissue removal.
"We are pushing the frontier of neurotechnology focusing on materials that are intended to interface seamlessly with the brain," said Nicolas Vachicouras, CEO and co-founder of Neurosoft Bioelectronics. "This milestone solidifies our leadership in soft, stretchable brain interfaces and paves the way for broader applications in neuroprosthetics and brain-computer interfaces."
"The Neurosoft flexible grid has been developed according to our clinical needs. The flexibility can be especially useful for recording small epileptic activity, like high frequency oscillations and for checking the surgical borders after initial tissue resection." said Prof. Maeike Zijlmans, epilepsy specialist at UMC Utrecht.
These first two successful trials mark the beginning of a larger, 12-patient study at UMC Utrecht, designed to validate the technology for broader clinical use. The ultimate goal is to secure European regulatory approval and make this high-resolution technology available to epilepsy surgery centers across Europe.
The success of this initiative is the result of close collaboration between Neurosoft Bioelectronics and UMC Utrecht, demonstrating how startups and hospitals can work together to bring cutting-edge medical technologies into real-world clinical settings. This work has been made possible through the support of the Wyss Center for Bio and Neuroengineering and Fongit, which have played a key role in fostering Neurosoft Bioelectronics’ technological and clinical advancements. Additionally, the study conducted at UMC Utrecht is funded by the European Research Council (ERC), reflecting the project's significance in advancing neurotechnology and epilepsy research.
About Neurosoft Bioelectronics
Neurosoft Bioelectronics Ltd. is a neurotechnology spin-off from the Swiss Federal Institute of Technology in Lausanne (EPFL) and accelerated by the Wyss Center for bio and neuroengineering. Neurosoft Bioelectronics is developing the next generation of soft minimally invasive brain interfaces for the treatment of severe neurological disorders. Its main product is a fully implantable Brain-Computer Interface (BCI) to treat severe tinnitus, a condition that affects 120M people worldwide. It is also developing a family of brain interfaces intended for monitoring during brain tumor and epilepsy resection surgery.
About UMC Utrecht
UMC Utrecht is one of the top-ranked academic medical centers in Europe with the core tasks of care, research and education. With more than 12,000 employees, UMC Utrecht is one of the largest public healthcare institutions in the Netherlands and the largest employer in the region. Our mission: together we improve the health of people and create the care of tomorrow. Together we create more value, because we believe that every person counts.
Research at UMC Utrecht is concentrated in six multidisciplinary programs, each with a number of disease targets. ‘Brain’ is one of these research programs. UMC Utrecht collaborates with many regional, national and international partners in the field of care, research and education.
Contacts:
Neurosoft Bioelectronics (Media relations) Nicolas Vachicouras nicolas@neurosoft-bio.com CH: +41 78 876 1469 / US: +1 914 233 4172
UMC Utrecht (Spokesperson) Margreeth Fernhout m.w.fernhout-4@umcutrecht.nl NL: +31 652 803 031